Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 401 426 4664

Website: www.allarity.com

Address:

123 E. Tarpon Ave., Tarpon Springs, United States

biotrade123 Jun. 8 at 8:17 PM

$ALLR can anyone list the next expected catalyst? if none on the horizon, this could sink further?

0 · Reply

biotrade123 Jun. 8 at 8:03 PM

$ALLR There it closes red again 😭😭

0 · Reply

TheWhiteNight Jun. 8 at 5:16 PM

$ALLR when 400% day?

1 · Reply

Amscru80 Jun. 8 at 4:32 PM

$ALLR @Love_To_Learn

0 · Reply

anachartanalyst Jun. 8 at 3:01 PM

$ALLR https://anachart.com/wp-content/uploads/2026/06/1780930877_soc-img.jpg

0 · Reply

MichaelSctock Jun. 8 at 2:52 PM

$ALLR ok, I’ll bite. Loading more for the big run. 100k shares if I can get my price……..

2 · Reply

Wody Jun. 8 at 2:41 PM

$ALLR

0 · Reply

biotrade123 Jun. 8 at 12:43 PM

$ALLR down pm? a downtrend? another p&d cycle? perhaps the arrival of some pumps is indicative of one??🤞🤞

1 · Reply

biotrade123 Jun. 8 at 1:38 AM

$ALLR if this closes red tomorrow it could plausibly be the base of a downtrend??🤞🤞

0 · Reply

biotrade123 Jun. 6 at 12:09 PM

$ALLR gave up gains made on thursday..😭😭

0 · Reply

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 8, 2026, 8:45 AM EDT - 4 weeks ago

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

2026-04-27T13:21:02.000Z - 6 weeks ago

Allarity receives notice of allowance from USPTO

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

2026-03-06T13:19:41.000Z - 3 months ago

Allarity closes $20M financing for stenoparib advancement

Mar 6, 2026, 8:00 AM EST - 3 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

2026-02-18T13:25:56.000Z - 3 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Feb 18, 2026, 8:15 AM EST - 3 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

2026-02-03T13:20:33.000Z - 4 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Feb 3, 2026, 8:00 AM EST - 4 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

2025-12-31T13:05:34.000Z - 5 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Dec 31, 2025, 8:00 AM EST - 5 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

2025-12-03T14:15:27.000Z - 6 months ago

Allarity files $50M mixed securities shelf

2025-11-14T14:06:08.000Z - 7 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Nov 14, 2025, 9:00 AM EST - 7 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

2025-09-25T21:25:29.000Z - 9 months ago

Allarity files to sell 1.56M shares of common stock for holders

2025-09-22T12:20:54.000Z - 9 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Sep 22, 2025, 8:00 AM EDT - 9 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

2025-08-27T01:00:00.000Z - 10 months ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-26T12:05:59.000Z - 10 months ago

Allarity announces FDA granted Fast Track designation to stenoparib

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 15, 2025, 4:30 PM EDT - 10 months ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

2025-07-28T09:50:42.000Z - 11 months ago

Allarity initiated with a Buy at Ascendiant

Jul 15, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2025-06-30T14:34:35.000Z - 1 year ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-27T12:10:38.000Z - 1 year ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

2025-06-02T12:30:27.000Z - 1 year ago

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

2025-04-25T12:07:11.000Z - 1 year ago

Allarity presents poster on new data on DRP for daratumumab

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

biotrade123 Jun. 8 at 8:17 PM

$ALLR can anyone list the next expected catalyst? if none on the horizon, this could sink further?

0 · Reply

biotrade123 Jun. 8 at 8:03 PM

$ALLR There it closes red again 😭😭

0 · Reply

TheWhiteNight Jun. 8 at 5:16 PM

$ALLR when 400% day?

1 · Reply

Amscru80 Jun. 8 at 4:32 PM

$ALLR @Love_To_Learn

0 · Reply

anachartanalyst Jun. 8 at 3:01 PM

$ALLR https://anachart.com/wp-content/uploads/2026/06/1780930877_soc-img.jpg

0 · Reply

MichaelSctock Jun. 8 at 2:52 PM

$ALLR ok, I’ll bite. Loading more for the big run. 100k shares if I can get my price……..

2 · Reply

Wody Jun. 8 at 2:41 PM

$ALLR

0 · Reply

biotrade123 Jun. 8 at 12:43 PM

$ALLR down pm? a downtrend? another p&d cycle? perhaps the arrival of some pumps is indicative of one??🤞🤞

1 · Reply

biotrade123 Jun. 8 at 1:38 AM

$ALLR if this closes red tomorrow it could plausibly be the base of a downtrend??🤞🤞

0 · Reply

biotrade123 Jun. 6 at 12:09 PM

$ALLR gave up gains made on thursday..😭😭

0 · Reply

MichaelSctock Jun. 5 at 2:23 PM

$ALLR any day now….

1 · Reply

ItUsuallyIs Jun. 5 at 1:32 PM

$ALLR

0 · Reply

Markshoemaker1 Jun. 5 at 4:53 AM

$ALLR I want a piece of that drug dealing money. It’s a disgrace to even invest in a satanic company but I hope to make some money so I can can bounce the fuck out. But you know the old saying. Play with fire…

1 · Reply

Garymoved Jun. 4 at 10:37 PM

$ALLR

0 · Reply

Wody Jun. 4 at 6:59 PM

$ALLR

0 · Reply

ka1954 Jun. 4 at 4:38 PM

$ALLR some of u idiots sell, it goes 15-20 cents and then it goes right back up. then why should anybody sell, just to rebuy 15 cents cheaper?

3 · Reply

biotrade123 Jun. 3 at 7:25 PM

$ALLR wheres the bottom??

1 · Reply

Khaled2626 Jun. 3 at 9:43 AM

$ALLR holding more than two years still in loss , Iam really dying out , who has some truth optimistic words not fake ??!! :( :( :(

3 · Reply

sixmilliondollarman Jun. 2 at 11:09 PM

$ALLR 8-K contract amendment for CEO Jensen reflects strong board alignment ahead of major milestones. Upgrading his contract protections locks him in ahead of data inflection and subsequent FDA engagements. Following recent wins—including securing a cash runway through 2028, launching SCLC trials at U.S. VA sites, and obtaining a USPTO patent allowance for the stenoparib DRP diagnostic—the board has solidified Jensen’s role as the face of the corporate turnaround. Reiterate Buy | PT $6.50

2 · Reply

focafoca99 Jun. 2 at 10:52 PM

$ALLR restructured its management services agreement, amending compensation and termination terms with its consulting CEO.

0 · Reply

Amscru80 Jun. 2 at 3:54 PM

$ALLR the best hidden gem!! 💎💎🚀🚀 $SLS

1 · Reply

CantAffordMe Jun. 2 at 2:22 PM

$ALLR squeeze this terd and take us all to kingdom come

0 · Reply

Market Cap	25.62M
Revenue (ttm)	320,000.00
Net Income (ttm)	-11.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,509.37%
Debt to Equity Ratio	0.21

Volume	107,039
Avg Vol	199,420
Day's Range	N/A - N/A
Shares Out	15.91M
Stochastic %K	21%
Beta	0.52
Analysts	Sell
Price Target	$9.75